Eli Lilly and Co.

Lilly looks to autoimmune drugs

January 27, 2010
J.K. Wall
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune diseases: The costs of treating them are growing twice as fast as the prescription drug market.
More

Lilly shares get boost from OK of rival's drug

January 26, 2010
 IBJ Staff and Bloomberg News
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators' clearance of a similar drug.
More

Biotech firm plans $28M Greenwood plant

January 19, 2010
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to help develop a cheaper form of insulin that could gain significant market share.
More

FDA letters scold Lilly, others over marketing materials

January 13, 2010
Associated Press
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately display information about the drug's side effects.
More

FDA cancels meeting to review Lilly's Cymbalta

January 5, 2010
Associated Press
The agency said the meeting was canceled "to allow time for the FDA to review new information" about a proposed new use for the drug.
More

Ruth Lilly remembered for 'selfless' giving

December 31, 2009
Andrea Muirragui Davis
Lilly, 94, who died Wednesday, gave away hundreds of millions of dollars of her fortune during her lifetime.
More

Eli Lilly and Co. heiress Ruth Lilly dies at 94

December 31, 2009
Associated Press
Over the course of her life, the last surviving great-grandchild of pharmaceutical magnate Eli Lilly gave away much of her inheritance.
More

Corporations bet on insiders to bend reform

December 30, 2009
J.K. Wall
Indianapolis health care heavyweights are among those spending $635 million, employing 166 former aides to key congressional leaders and committees in health reform process.
More

Lilly scurries to get out from under Zyprexa cloud

December 26, 2009
J.K. Wall
Another year of rapid change at Eli Lilly and Co. did little to move the company out from under the cloud cast by its best-selling drug, Zyprexa.
More

To keep sales force busy, Lilly takes on new drug

December 24, 2009
J.K. Wall
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel to push.
More

Lilly pays $90 million for autoimmune drug

December 21, 2009
 IBJ Staff
By acquiring an experimental medicine for rheumatoid arthritis, the Indianapolis-based drugmaker is increasing its focus on autoimmune diseases.
More

Senate rejects drug-importation proposal

December 16, 2009
 IBJ Staff and Associated Press
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers such as Indianapolis-based Eli Lilly and Co. a victory.
More

Lilly wins approval for long-acting Zyprexa

December 14, 2009
J.K. Wall
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
More

Eli Lilly's shares slip after it forecasts mixed profits in coming years

December 10, 2009
 IBJ Staff and Associated Press
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results could fall precipitously.
More

Lilly launching new venture capital fund

December 10, 2009
J.K. Wall
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's drug pipeline.
More

Ariad asks court to restore patent-suit win against Lilly

December 8, 2009
 IBJ Staff
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent claim.
More

Builder looks to cold storage for steady work in a weak economyRestricted Content

December 5, 2009
Brock Benefiel
Cold storage might become a hot business for a building contractor.
More

Part of Mississippi's Zyprexa case against Lilly dismissed

December 2, 2009
 IBJ Staff
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges improper marketing of antipsychotic drug Zyprexa for unapproved uses.
More

Lilly extends research pact with India firm

December 1, 2009
 IBJ Staff
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five years.
More

Lilly's Cymbalta wins new approval for anxiety disorder

November 30, 2009
J.K. Wall
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
More

Lilly stock droops after rival claims faster-acting impotence pill

November 18, 2009
 IBJ Staff
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
More

Lilly to pay Utah $24 million to settle Zyprexa suit

November 11, 2009
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic drug Zyprexa.
More

Lilly, WellPoint CEOs pin hopes on Senate

November 11, 2009
J.K. Wall
Drugmaker and health insurer bemoan aspects of House health reform bill and hope Senate crafts more industry-friendly bill.
More

Lilly reducing sales force by 191 as part of larger restructuring

November 2, 2009
Eli Lilly and Co. has notified the state that it plans to eliminate 191 sales jobs as part of a company-wide restructuring announced in September that ultimately will result in 5,500 job cuts by the end of 2011.
More

TechPoint to focus on IT firms specializing in medical, life sciences sectorsRestricted Content

October 31, 2009
Chris O'Malley
Long tracking the emergence of information technology firms involved in the health and life sciences sector, the state’s IT trade group, TechPoint, is undergoing a mitosis of sorts to help fuel the trend. It has created Advancing Life Science & Health Care Information Technology, or ALHIT, which will focus on growing this subset of the IT realm.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

ADVERTISEMENT